Ecoporc Shiga

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

organiżmi ġenetikament modifikati rikombinanti Shiga-tossina-2c-antiġen

Available from:

CEVA Santé Animale

ATC code:

QI09AB02

INN (International Name):

genetically modified Shiga-toxin-2e antigen

Therapeutic group:

Majjali

Therapeutic area:

Immunologicals for suidae, Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)

Therapeutic indications:

Immunizzazzjoni attiva ta 'qżieqeż mill-età ta' erbat ijiem, biex titnaqqas il-mortalità u sinjali kliniċi ta ' edima l-mard ikkawżat mill-Shiga-tossina 2c prodotti minn Escherichia coli (STEC). Il-bidu tal-immunità: 21 jum wara t-tilqima. Tul ta 'żmien ta' l-immunità: 105 jum wara t-tilqima.

Product summary:

Revision: 4

Authorization status:

Awtorizzat

Authorization date:

2013-04-10

Patient Information leaflet

                                15
B. FULJETT TA' TAGĦRIF
16
FULJETT TA’ TAGĦRIF
ECOPORC SHIGA SUSPENSJONI GĦALL-INJEZZJONI GĦAL QŻIEQEŻ
1.
L-ISEM U L-INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-
TQEGĦID FIS-SUQ U TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦALL-
MANIFATTURA RESPONSABBLI GĦALL-ĦRUĠ TAL-LOTT, JEKK DIFFERENTI
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq:
Ceva Santé Animale
10 av. de La Ballastière
33500 Libourne
Franza
Manifattur responsabbli għall-ħruġ tal-lott:
IDT Biologika GmbH
Am Pharmapark
06861 Dessau-Rosslau
Il-Ġermanja
Ceva-Phylaxia Veterinary Biologicals Co. Ltd.
Szállás u. 5.
1107 Budapest
Ungerija
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Ecoporc SHIGA Suspensjoni għall-injezzjoni għal qżieqeż
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
Kull doża ta’ 1 ml fiha:
SUSTANZI ATTIVI:
Antiġen Stx2e rikombinanti modifikat ġenetikament:
≥ 3.2 x 10
6
Unitajiet ELISA
_ _
SUSTANZA MHUX ATTIVA:
Aluminju (bħala idrossidu)
massimu 3.5 mg
INGREDJENT IEĦOR:
Thiomersal
massimu 0.115 mg
Dehra wara li tħawdu: suspensjoni omoġena minn safranija sa kannella
4.
INDIKAZZJONI(JIET)
Tilqima attiva ta’ qżieqeż mill-età ta’ 4 ijiem, biex titnaqqas
il-mortalità u sinjali kliniċi ta’ mard tal-
edema kkawżat minn tossina Stx2e prodotta minn
_E. coli_
(STEC).
Bidu tal-immunità: 21 jum wara l-vaċċin
Tul tal-immunità:
105 jum wara l-vaċċin
17
5.
KONTRAINDIKAZZJONIJIET
Tużax f’każijiet ta’ sensittività eċċessiva għall-ingredjent
attiv, għas-sustanza mhux attiva jew
kwalunkwe ingredjent ieħor.
6.
EFFETTI MHUX MIXTIEQA
Reazzjonijiet lokali żgħar ħafna bħal nefħa ħafifa fis-sit
tal-injezzjoni (massimu ta’ 5 mm), jistgħu’
jiġu osservata b’mod komuni, iżda dawn ir-reazzjonijiet huma
temporanji u jfiqu fi żmien qasir (sa
sebat ijiem) u mingħajr ebda kura. B’mod komuni tista’ sseħħ
żieda żgħira fit-temperatura tal-ġisem
(massimu ta’ 1.7°C) wara l-injezzjoni. Iżda dawn ir-reazzjonijiet
jonqsu fi żmien qasir (massimu ta’
jumejn) mingħajr 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Ecoporc SHIGA Suspensjoni għall-injezzjoni għal qżieqeż
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Kull doża ta’ 1 ml fiha:
SUSTANZA ATTIVA :
Antiġen Stx2e rikombinanti modifikat ġenetikament:
≥ 3.2 x 10
6
Unitajiet ELISA
SUSTANZA MHUX ATTIVA:
Aluminju (bħala idrossidu)
massimu 3.5 mg
INGREDJENT IEĦOR:
Thiomersal
massimu 0.115 mg
Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1
3.
GĦAMLA FARMAĊEWTIKA
Suspensjoni għall-injezzjoni.
Id-dehra wara li tħawdu: suspensjoni omoġena minn safranija sa
kannella.
4
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Qżieqeż.
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Tilqima attiva ta’ qżieqeż żgħar mill-età ta’ 4 ijiem, biex
titnaqqas il-mortalità u sinjali kliniċi ta’ mard
tal-edema kkawżat minn tossina Stx2e prodotta minn
_E. coli_
(STEC).
Bidu tal-immunità: 21 jum wara l-vaċċinazzjoni
Tul tal-immunità:
105 jum wara l-vaċċinazzjoni
4.3
KONTRAINDIKAZZJONIJIET
Tużax f'każijiet ta' sensittivita għall-ingredjent attiv;
ingredjenti mhux attivi jew ingredjenti oħra.
4.4
TWISSIJIET SPEĊJALI 
Laqqam biss annimali li jkunu f’saħħithom.
4.5
PREKAWZJONIJIET SPEĊJALI GĦALL-UŻU
Prekawzjonijiet speċjali għall-użu fl-annimali
Mhux applikabbli.
3
Prekawzjonijiet speċjali li għandhom jittieħdu mill-persuna li
tamministra l-prodott mediċinali
veterinarju lill-annimali
F'każ li tinjetta lilek innifsek jew li tibilgħu b’mod
aċċidentali, fittex tabib mal-ewwel u qis li turih il-
fuljett ta' tagħrif jew it-tikketta.
4.6
EFFETTI MHUX MIXTIEQA (FREKWENZA U GRAVITÀ)
Reazzjonijiet lokali żgħar ħafna bħal nefħa ħafifa fis-sit
tal-injezzjoni (massimu ta’ 5 mm) jistgħu jiġu
osservati, u huma komuni. Dawn ir-reazzjonijiet huma temporanji u
jfiqu fi żmien qasir (sa sebat
ijiem) mingħajr
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 18-09-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 18-09-2020
Public Assessment Report Public Assessment Report Bulgarian 16-05-2013
Patient Information leaflet Patient Information leaflet Spanish 18-09-2020
Public Assessment Report Public Assessment Report Spanish 16-05-2013
Patient Information leaflet Patient Information leaflet Czech 18-09-2020
Public Assessment Report Public Assessment Report Czech 16-05-2013
Patient Information leaflet Patient Information leaflet Danish 18-09-2020
Public Assessment Report Public Assessment Report Danish 16-05-2013
Patient Information leaflet Patient Information leaflet German 18-09-2020
Public Assessment Report Public Assessment Report German 16-05-2013
Patient Information leaflet Patient Information leaflet Estonian 18-09-2020
Public Assessment Report Public Assessment Report Estonian 16-05-2013
Patient Information leaflet Patient Information leaflet Greek 18-09-2020
Public Assessment Report Public Assessment Report Greek 16-05-2013
Patient Information leaflet Patient Information leaflet English 18-09-2020
Public Assessment Report Public Assessment Report English 16-05-2013
Patient Information leaflet Patient Information leaflet French 18-09-2020
Public Assessment Report Public Assessment Report French 16-05-2013
Patient Information leaflet Patient Information leaflet Italian 18-09-2020
Public Assessment Report Public Assessment Report Italian 16-05-2013
Patient Information leaflet Patient Information leaflet Latvian 18-09-2020
Public Assessment Report Public Assessment Report Latvian 16-05-2013
Patient Information leaflet Patient Information leaflet Lithuanian 18-09-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 18-09-2020
Public Assessment Report Public Assessment Report Lithuanian 16-05-2013
Patient Information leaflet Patient Information leaflet Hungarian 18-09-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 18-09-2020
Public Assessment Report Public Assessment Report Hungarian 16-05-2013
Patient Information leaflet Patient Information leaflet Dutch 18-09-2020
Public Assessment Report Public Assessment Report Dutch 16-05-2013
Patient Information leaflet Patient Information leaflet Polish 18-09-2020
Public Assessment Report Public Assessment Report Polish 16-05-2013
Patient Information leaflet Patient Information leaflet Portuguese 18-09-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 18-09-2020
Public Assessment Report Public Assessment Report Portuguese 16-05-2013
Patient Information leaflet Patient Information leaflet Romanian 18-09-2020
Public Assessment Report Public Assessment Report Romanian 16-05-2013
Patient Information leaflet Patient Information leaflet Slovak 18-09-2020
Public Assessment Report Public Assessment Report Slovak 16-05-2013
Patient Information leaflet Patient Information leaflet Slovenian 18-09-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 18-09-2020
Public Assessment Report Public Assessment Report Slovenian 16-05-2013
Patient Information leaflet Patient Information leaflet Finnish 18-09-2020
Public Assessment Report Public Assessment Report Finnish 16-05-2013
Patient Information leaflet Patient Information leaflet Swedish 18-09-2020
Public Assessment Report Public Assessment Report Swedish 16-05-2013
Patient Information leaflet Patient Information leaflet Norwegian 18-09-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 18-09-2020
Patient Information leaflet Patient Information leaflet Icelandic 18-09-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 18-09-2020
Patient Information leaflet Patient Information leaflet Croatian 18-09-2020

View documents history